THCP
THCP at a glance
Naturally occurring
Psychoactive
Cannabinoid type
Discovery year
Also known as
Molecular formula
C23H34O2
CB1 receptor interaction
CB2 receptor interaction
What is THCP?
THCP is a rare intoxicating phytocannabinoid and the seven-carbon homologue of Delta-9-THC. It occurs naturally in Cannabis sativa in trace amounts, together with its acidic precursor THCPA. THCP is generally considered around 7× as psychoactively potent as Delta-9-THC, although its actual human potency has not been established in controlled studies.
THCP has the same basic THC structure as Delta-9-THC but contains a seven-carbon (heptyl) side chain instead of the five-carbon (pentyl) side chain of Delta-9-THC. This longer side chain substantially changes its biological activity. The naturally occurring form is trans-(6aR,10aR)-Delta-9-THCP, while other stereoisomers can also be produced synthetically. Delta-8-THCP is a separate positional isomer.
Because natural concentrations are extremely low, commercial THCP is generally produced synthetically and supplied as a high-purity, yellow or amber viscous distillate. Its unsaturated THC-type structure is expected to make it more susceptible to oxidation than its fully hydrogenated counterpart HHCP.
THCP was first isolated and fully identified from the Italian medicinal cannabis variety FM2 in 2019, alongside CBDP. Its discovery attracted significant attention because of its unusually long side chain and reported potency. Commercial interest increased rapidly in Europe during the early 2020s, where THCP became available in some EU countries as an alternative to conventional THC products. It is now among the more widely encountered newer cannabinoids in the European market, although scientific research on human effects, safety and pharmacokinetics remains limited.
How THCP works in the human body
THCP activates cannabinoid receptors involved in psychoactive, neurological and immune signalling and is theoretically estimated at around 4x the psychoactive potency of Delta-9-THC. It shows both strong CB1 and CB2 binding. With oral intake, it’s likely to metabolise to 11-OH-THCP, although this remains insufficiently studied.
CB1 receptor
The main cannabinoid receptor in the brain, responsible for THC’s intoxicating effects. THCP binds CB1 approximately 33x more strongly than Delta-9-THC, which is attributed largely to its seven-carbon side chain fitting particularly effectively within the receptor’s binding pocket.
Functional testing shows a much smaller difference than binding affinity alone suggests. Compared with Delta-9-THC, THCP showed approximately 1.46x greater functional potency in a human CB1 signalling assay, while reaching approximately 0.8x its maximum response. This demonstrates that substantially stronger receptor binding does not translate directly into an equally large increase in functional CB1 signalling.
Animal evidence nevertheless indicates stronger overall cannabinoid activity. THCP markedly reduced movement in mice at 2.5 mg/kg and produced significant effects, while approximately 10 mg/kg Delta-9-THC is typically required in comparable testing.
Considering its 33x stronger reported CB1 binding, 1.46x greater functional potency, user reports, and effects appearing at roughly 2 to 4x lower doses in mice, THCP is theoretically estimated at around 4x the psychoactive potency of Delta-9-THC. This multiplier is a calculated estimate rather than a directly measured human potency ratio.
CB2 receptor
The main cannabinoid receptor in the immune system, involved in regulating immune cell activity and inflammatory responses. THCP binds CB2 approximately 5.8x more strongly than Delta-9-THC in the original receptor-binding research. This strong affinity suggests substantial potential for CB2 interaction, but specific CB2-mediated immune or inflammatory effects of THCP have not been established in humans.
Metabolism
Human liver-microsome research shows that THCP undergoes hydroxylation followed by further oxidation to carboxylated metabolites, broadly resembling Delta-9-THC metabolism. User reports prolonged effects after oral THCP intake, lasting up to several days in high doses. 11-OH-THCP as metabolite is a probable cause, supported by earlier mouse metabolism research, but no direct human research has taken place on THCP metabolites.
Human safety status
No direct evidence currently shows that THCP causes organ toxicity or other specific toxicological damage, although dedicated human safety studies are lacking. However, its high psychoactive potency means that strong and prolonged effects can occur at higher doses, with reports describing acute psychological reactions and negative side effects. Repeated and long-term exposure remain unstudied, so a reliable human safety profile cannot yet be established.
THCP interactions with other compounds
Important disclaimer
This information is provided for educational and technical reference only. Interaction data can change as new research becomes available and may be incomplete or outdated. The real relevance of any interaction depends strongly on dose, route of administration, timing, formulation and individual metabolism. Readers should do their own research and consult a qualified healthcare professional before making decisions involving medicines, alcohol, nicotine, cannabinoids or other compounds. Elementra's products and information are intended for research, production and technical use only and are not intended for human consumption.
No Known Interactions Identified
Current Evidence
Limited Data
No sufficiently supported specific interactions between THCP and other cannabinoids, common substances or medicines have currently been identified. THCP has been directly studied for cannabinoid receptor activity and laboratory metabolism, but research has not yet shown that another compound meaningfully changes THCP exposure or effects, or that THCP meaningfully changes the exposure or effects of another compound. This should not be interpreted as THCP having no interactions. Interactions may exist, but they have not yet been identified or characterized by research.
This content does not constitute advice
All information in the Cannabinoid Knowledge Hub is provided solely for educational and scientific purposes. It does not constitute medical advice, usage advice, dosage guidance or instructions for mixing, combining or consuming substances.
Discussions of effects, interactions and risks are descriptive only and should not be interpreted as a recommendation or encouragement to use or combine any substance. Visitors are responsible for complying with all applicable laws and regulations in their country or jurisdiction. Nothing in the Knowledge Hub may be used to support illegal activity.
Read the full disclaimer